Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04232566 · ClinicalTrials.gov registry record
Investigating the Link Between Type 2 Immunity and NAFLD in Human Obesity
A clinical trial of NASH - Nonalcoholic Steatohepatitis and Obesity, Morbid, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- 60
- Enrollment target
- 1
- Study location
NCT04232566 is a study of NASH - Nonalcoholic Steatohepatitis and Obesity, Morbid that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 60 participants, below the 267-participant average among 27 other NASH - Nonalcoholic Steatohepatitis trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04232566, a study of NASH - Nonalcoholic Steatohepatitis and Obesity, Morbid, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being done to better understand the relationship between inflammation in adipose tissue (AT), abnormal deposition of fat around the liver and how this affects its appearance and function and ultimately insulin resistance.
Conditions Studied
Interventions
- PROCEDURE Bariatric surgery
Study Locations (1)
Arizona
- Mayo Clinic in Arizona - Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2022-02-20 |
| Est. Completion | 2027-12-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04232566
The ClinicalTrials.gov registry entry for NCT04232566 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 267-participant average among 27 other NASH - Nonalcoholic Steatohepatitis trials with a reported enrollment target (78% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with NASH - Nonalcoholic Steatohepatitis appearing as the primary indexed condition, and to 1 intervention - of which Bariatric surgery is the first listed.
NCT04232566 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT04232566 about?
NCT04232566 is a clinical study titled "Investigating the Link Between Type 2 Immunity and NAFLD in Human Obesity". This study is being done to better understand the relationship between inflammation in adipose tissue (AT), abnormal deposition of fat around the liver and how this affects its appearance and function and ultimately insulin resistance.
What is the current status of trial NCT04232566?
This trial is currently recruiting. The enrollment target is 60 participants. The study started on 2022-02-20. Estimated completion is 2027-12-30.
What conditions does trial NCT04232566 study?
This clinical trial studies the following conditions: NASH - Nonalcoholic Steatohepatitis, Obesity, Morbid, Chronic Inflammation.
What interventions are being tested in trial NCT04232566?
The interventions under investigation include: Bariatric surgery (PROCEDURE).
Who is sponsoring clinical trial NCT04232566?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04232566 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for NASH - Nonalcoholic Steatohepatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
RECRUITING · NA
-
Feasibility, Safety and Acceptability of a Mobile Health Delivered Exercise Training Program in Patients With Nonalcoholic Steatohepatitis
RECRUITING · NA
-
Estrogen Administration for the Treatment of NASH in Postmenopausal Women
RECRUITING · Phase 3
-
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
RECRUITING · Phase 3
-
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
RECRUITING · Phase 3
-
Vertical Sleeve Gastrectomy and Lifestyle Modification for the Treatment of Non-Alcoholic Steatohepatitis
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.